These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30201241)

  • 41. Beyond fast track for drug approvals.
    Roberts TG; Chabner BA
    N Engl J Med; 2004 Jul; 351(5):501-5. PubMed ID: 15282359
    [No Abstract]   [Full Text] [Related]  

  • 42. Drug approval triggers debate on future direction for cancer treatments.
    Frantz S
    Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324
    [No Abstract]   [Full Text] [Related]  

  • 43. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
    Bach PB; Giralt SA; Saltz LB
    JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
    [No Abstract]   [Full Text] [Related]  

  • 44. Oncology update.
    Smart M
    Oncol Nurs Forum; 2011 Jul; 38(4):485-6. PubMed ID: 21708539
    [No Abstract]   [Full Text] [Related]  

  • 45. Seamless Oncology-Drug Development.
    Prowell TM; Theoret MR; Pazdur R
    N Engl J Med; 2016 May; 374(21):2001-3. PubMed ID: 27074059
    [No Abstract]   [Full Text] [Related]  

  • 46. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 47. Upcoming market catalysts in Q4 2020.
    Pablos L
    Nat Rev Drug Discov; 2020 Oct; 19(10):661. PubMed ID: 32901130
    [No Abstract]   [Full Text] [Related]  

  • 48. Patient-reported outcomes supporting anticancer product approvals.
    Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
    J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment.
    Gyawali B; Hwang TJ; Vokinger KN; Booth CM; Amir E; Tibau A
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():374-387. PubMed ID: 31099613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tissue-agnostic cancer drug pipeline grows, despite doubts.
    Garber K
    Nat Rev Drug Discov; 2018 Apr; 17(4):227-229. PubMed ID: 29520093
    [No Abstract]   [Full Text] [Related]  

  • 51. Cancer biotherapy: the field matures.
    Oldham RK
    Cancer Biother; 1995; 10(2):91-3. PubMed ID: 7663577
    [No Abstract]   [Full Text] [Related]  

  • 52. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020.
    Miljkovic MD; Tuia JE; Olivier T; Haslam A; Prasad V
    JAMA Intern Med; 2022 Dec; 182(12):1319-1320. PubMed ID: 36315136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. US Food and Drug Administration approves first cancer treatment for any solid tumors with specific biomarker.
    Cancer; 2017 Oct; 123(19):3652-3653. PubMed ID: 28940329
    [No Abstract]   [Full Text] [Related]  

  • 54. New Approvals in Cancer Treatment.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749878
    [No Abstract]   [Full Text] [Related]  

  • 55. Selection bias, phase II trials, and the FDA accelerated approval process.
    George SL
    J Natl Cancer Inst; 2003 Sep; 95(18):1351-2. PubMed ID: 13130101
    [No Abstract]   [Full Text] [Related]  

  • 56. Raising the bar of efficacy for drug approval requires an understanding of patient diversity.
    Berger ML; Eck S; Ruberg SJ
    J Clin Oncol; 2010 Jul; 28(20):e343-4; author reply e345. PubMed ID: 20458030
    [No Abstract]   [Full Text] [Related]  

  • 57. Programs established by FDA to expedite patient access to medications.
    Motl S; Miller SJ; Burns P
    Am J Health Syst Pharm; 2003 Feb; 60(4):339-45. PubMed ID: 12625215
    [No Abstract]   [Full Text] [Related]  

  • 58. FDA new drug approvals in Q1 2021.
    Urquhart L
    Nat Rev Drug Discov; 2021 May; 20(5):334. PubMed ID: 33854219
    [No Abstract]   [Full Text] [Related]  

  • 59. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
    Mailankody S; Prasad V
    JAMA Oncol; 2017 Jul; 3(7):889-890. PubMed ID: 27892992
    [No Abstract]   [Full Text] [Related]  

  • 60. Cancer drugs remain FDA approved despite lack of benefit, study finds.
    McCarthy M
    BMJ; 2016 Dec; 355():i6568. PubMed ID: 27923801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.